A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR [epidermal growth factor receptor] Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-Based Regimens.

Trial Profile

A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR [epidermal growth factor receptor] Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-Based Regimens.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2011

At a glance

  • Drugs Everolimus (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 13 May 2011 Trial phase changed from II/III to II as reported by ClinicalTrials.gov.
    • 13 May 2011 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 23 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2006-0806).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top